↓ Skip to main content

Dove Medical Press

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, December 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

policy
1 policy source

Citations

dimensions_citation
26 Dimensions

Readers on

mendeley
59 Mendeley